- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01121432
Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)
Although mediastinal tuberculous lymphadenopathy is not rare in adults of such an abnormality. Isolated mediastinal without a parenchymal lung lesion in adults is unusual with the incidence of 0.25%-5.8%. It occurs most commonly in Asian and black people, and presents a diagnostic problem. The definite diagnosis requires microbiology or pathology study.
Cervical mediastinoscopy remained the gold standard to sample the mediastnial lymph nodes, but this technique can access lymph node station 1-4, 7 only. EBUS-TBNA allows the mediastinal lymph nodes to be targeted in the areas accessible to cervical mediastinoscopy, as well as some hilar nodes (lymph node stations 2-4, 7, 10-12). Currently, the main indication of EBUS-TBNA is the mediastinal nodal staging of NSCLC after recent meta-analyses established the comparable sensitivity and specificity of nodal staging by EBUS-TBNA and cervical mediastinoscopy. Theoretically, mediastnial tuberculous lymphadenopathy could be diagnosed by the method of EBUS-TBNA. Douglas F. Johnson was the first doctor to report 2 cases of mediastinal tuberculous lymphadenopathy diagnosed by EBUS-TBNA in 2009. There are currently no much data on the use of this technique in this field. The investigators plan to perform a prospective single-center study to investigate the diagnostic efficacy of mediastinal tuberculous lymphadenopathy by sampling the culprit nodes via EBUS-TBNA. Concomitant sputum specimen for acid-fast stain and mycobacterial culture were collected as well.
Study Overview
Status
Intervention / Treatment
Detailed Description
Although mediastinal tuberculous lymphadenopathy is much more common as a manifestation of primary tuberculosis in children, the presentation in adults of such an abnormality is not rare. In a large series reported in 1959 by Lyons and coworkers, tuberculosis was the 5th commonest cause of mediastinal enlargement, accounting for 6% of 782 cases. Intrathoracic lymphadenitis had been found to be present in between 0.5% and 26%.
However, isolated mediastinal without a parenchymal lung lesion in adults is unusual with the incidence of 0.25%-5.8%. It occurs most commonly in Asian and black people, and presents a diagnostic problem. Although chest CT findings such as nodes with central low attenuation and peripheral rim enhancement are suggestive, the definite diagnosis requires microbiology or pathology study.
Cervical mediastinoscopy remained the gold standard to sample the mediastnial lymph nodes, but this technique can access lymph node station 1-4, 7 only. EBUS-TBNA allows the mediastinal lymph nodes to be targeted in the areas accessible to cervical mediastinoscopy, as well as some hilar nodes (lymph node stations 2-4, 7, 10-12).
Kazuhiro Yasufuku had published the first report of rear-time EBUS-TBNA in evaluating mediastinal lymphadenopathy in 2004. Currently, the main indication of EBUS-TBNA is the mediastinal nodal staging of NSCLC after recent meta-analyses established the comparable sensitivity and specificity of nodal staging by EBUS-TBNA and cervical mediastinoscopy. Efficacy in evaluation of other disease processes such as sarcoidosis and lymphoma has also been established.
Theoretically, mediastnial tuberculous lymphadenopathy could be diagnosed by the method of EBUS-TBNA. Douglas F. Johnson was the first doctor to report 2 cases of mediastinal tuberculous lymphadenopathy diagnosed by EBUS-TBNA in 2009. There are currently no much data on the use of this technique in this field.
We plan to perform a prospective single-center study to investigate the diagnostic efficacy of mediastinal tuberculous lymphadenopathy by sampling the culprit nodes via EBUS-TBNA. Concomitant sputum specimen for acid-fast stain and mycobacterial culture were collected as well.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Chao-Chi Ho
- Phone Number: 886-972651317
- Email: ccho1203@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients with mediastinal lymphadenopathy of unknown etiology
- All patients signed informed consent before the procedure.
Exclusion Criteria:
- Age less than 18 years
- Bleeding diathesis (INR>1.4 or platelet count<10k/mcl)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Mediastinal lymphadenopathy
|
One time for aspiration/biopsy.
The duration about 1-2 hour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The ratio of tuberculous mediastinal lymphadenopathy
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chao-Chi Ho, PhD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201003061R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mediastinal Lymphadenopathy
-
Phan Quang HieuUniversity of Medicine and Pharmacy at Ho Chi Minh CityRecruiting
-
University Hospital, Strasbourg, FranceRecruitingMediastinal Lymphadenopathy | Diffuse Interstitial Lung Diseases | Mediastinal LesionsFrance
-
China-Japan Friendship HospitalRecruitingLymphadenopathy Hilar | Lymphadenopathy MediastinalChina
-
Christopher KappDuke University; University of California, DavisActive, not recruitingMediastinal and Hilar LymphadenopathyUnited States
-
Sanjay Gandhi Postgraduate Institute of Medical...CompletedMediastinal Lymphadenopathy | Hilar LymphadenopathyIndia
-
China-Japan Friendship HospitalCompleted
-
China-Japan Friendship HospitalNot yet recruiting
-
National Taiwan University HospitalUnknown
-
Third Military Medical UniversityHeidelberg UniversityCompletedMediastinal LymphadenopathyChina, Germany
-
Royal Brompton & Harefield NHS Foundation TrustUnknown
Clinical Trials on endobronchial ultrasound-guided transbronchial needle aspiration
-
Poitiers University HospitalCompletedEndobronchial Transbronchial Needle Aspiration Lung Cancer Procore
-
Western University, CanadaCompletedLung Cancer | Thoracic Cancer | Mediastinal LymphadenopathyCanada
-
China-Japan Friendship HospitalNot yet recruiting
-
Medical University of WarsawWarsaw University of TechnologyUnknownLung Cancer, | Mediastinal Tumors, | Lymphomas, | Sarcoidosis,Poland
-
University Health Network, TorontoRecruitingSuspected SarcoidosisCanada
-
M.D. Anderson Cancer CenterCompleted
-
Beijing Friendship HospitalCompletedLung Cancer | Tuberculosis | SarcoidosisChina
-
London Health Sciences Centre Research Institute...Academic Medical Organization of Southwestern OntarioRecruitingNon-Small Cell Lung CancerCanada
-
China-Japan Friendship HospitalNot yet recruiting